Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Amgen Inc. (NASDAQ:AMGN) is one of the 7 Most Profitable Value Stocks to Buy Right Now. Amgen Inc. (NASDAQ:AMGN) is one of ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amgen AMGN announced positive top-line results from a late-stage study evaluating the subcutaneous (under the skin or SC) formulation of its blockbuster drug Tepezza (teprotumumab) in patients with ...

Amgen (NasdaqGS:AMGN) released Phase 3 data for a subcutaneous, on-body injector version of TEPEZZA for Thyroid Eye Disease.

Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults with moderate to severe active thyroid eye disease (T ...

Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line. In 2024, when ...

Amgen Inc. ends 2025 on a high note. Thanks to strong sales of Repatha and Imdelltra, it raised its full-year 2025 revenue guidance from $35-$36 billion to $35.8-$36.6 billion. So, sales of Repatha, a ...